封面
市場調查報告書
商品編碼
1733589

全球經皮貼片市場規模(依產品類型、應用、地區、預測):

Global Transdermal Skin Patches Market Size By Product Type (Single-layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive), By Application (Neurologic Conditions, Pain Management), By Geographic Scope And Forecast

出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

經皮貼片市場規模及預測

預計 2024 年經皮貼片市場規模將達到 89.2 億美元,到 2032 年將達到 113.3 億美元,2026 年至 2032 年的複合年成長率為 4.87%。

經皮貼片是一種新型的藥物輸送裝置,它透過皮膚分配藥物,使藥物被全身吸收進入血液。這些貼片由三層組成:背襯、藥物儲存器或基質和黏合層。該藥物以定時方式釋放並透過皮膚層吸收,避免了胃腸道和首過代謝。

由於其多功能性和透過皮膚輸送藥物和治療物質的有效性,它變得越來越受歡迎,因為它可用於各種應用。其主要用途之一是治療糖尿病和高血壓等慢性疾病。例如,胰島素貼片可以讓糖尿病患者無需針刺即可調節血糖值,從而提高患者的依從性和舒適度。

隨著技術和材料科學的突破,預計未來它將變得更加普及。微針和微針貼片的創新可以提高藥物的吸收率,並且能夠輸送通常難以經皮給藥的較大分子,例如生技藥品和疫苗。

經皮貼片的全球市場動態

影響全球經皮貼片市場的關鍵市場動態是:

關鍵市場促進因素

慢性病盛行率上升:糖尿病、高血壓和疼痛相關疾病等慢性病盛行率上升是經皮貼片產業發展的主要驅動力。這些疾病通常需要長期用藥,因此經皮給藥是一種很有前景的選擇。

藥物傳遞技術的進步:微針、奈米技術和更好的皮膚滲透技術等經皮給藥的創新顯著提高了皮膚貼劑的功效和適用性。這些發展使得能夠輸送更廣泛的藥物,包括難以透過傳統方法給藥的生技藥品和大分子。

對患者依從性和便利性的需求不斷增加:經皮吸收貼片作為口服藥物和注射劑的使用者友善替代品越來越受歡迎,可提高患者的依從性。貼片很受患者歡迎,因為它們使用方便、敷貼時無痛,且敷貼頻率較低。

主要挑戰

配方相容性有限:並非所有藥物都適合包裝為經皮吸收貼片。某些藥物由於其分子大小或特性而穿透表皮屏障的能力有限。這限制了可透過經皮的治療方法類型,導致與口服或注射劑相比市場規模較小。

皮膚刺激和過敏反應:有些患者持續使用貼片可能會出現皮膚刺激、過敏反應或不適。這些副作用可能會導致患者依從性較差,因為不適感會使他們不願意遵循規定的治療方法。製造商必須不斷解決生物相容性和皮膚耐受性問題,以提高患者的接受度。

製造和品管:經皮貼片採用複雜的技術和廣泛的品管措施製造。製造條件的變化會導致藥物輸送率和貼片功能的變化。在整個製造過程中確保一致性和保持良好的品質至關重要,但也可能是一個挑戰,特別是對於技術不太先進的小公司。

主要趨勢

技術進步:材料和製造技術的重大進步提高了經皮吸收貼片的有效性和安全性。例如,微針技術透過在皮膚中創建微通道實現更有效的藥物輸送,從而加快吸收速度。此外,使用感測器等智慧技術來監測藥物管理和患者依從性也越來越受歡迎。

慢性病管理需求不斷增加:糖尿病、高血壓和疼痛管理問題等慢性病的盛行率不斷上升,推動了對經皮貼片的需求。這些貼片提供了一種簡單、非侵入性的口服藥物替代品,提高了患者的依從性和生活品質。

以病人為中心的解決方案:人們越來越重視個人化醫療和以病人為中心的醫療保健解決方案。經皮貼片的製造是為了滿足個別患者的需求,包括調整劑量和客製化給藥方案。這種方法在疼痛管理中尤其重要,因為客製化的貼片可以提供精確的針對性緩解。

目錄

第1章 引言

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章:已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章 市場概述

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

第5章經皮貼片市場(依產品類型)

  • 概述
  • 單層黏合劑
  • 多層黏合劑
  • 水庫
  • 蒸氣補丁
  • 矩陣

第6章經皮貼片市場(依應用)

  • 概述
  • 神經系統疾病
  • 疼痛管理
  • 尼古丁戒斷
  • 心血管疾病

第7章經皮貼片市場(按地區)

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區
    • 拉丁美洲
    • 中東和非洲

第8章 競爭態勢

  • 概述
  • 各公司市場排名
  • 主要發展策略

第9章 公司簡介

  • Teva Pharmaceuticals USA Inc.
  • Novartis AG
  • Teikoku Pharma USA Inc.
  • Mylan Inc.
  • 3M
  • Luye Pharma Group
  • Purdue Pharma Manufacturing LP
  • Henan Lingrui Pharmaceutical Ltd
  • Mundipharma

第10章 重大進展

  • 產品發布/開發
  • 合併與收購
  • 業務擴展
  • 夥伴關係與合作

第11章 附錄

  • 相關調查
簡介目錄
Product Code: 75029

Transdermal Skin Patches Market Size and Forecast

Transdermal Skin Patches Market size was valued at USD 8.92 Billion in 2024 and is projected to reach USD 11.33 Billion by 2032, growing at a CAGR of 4.87% from 2026 to 2032.

Transdermal skin patches are novel drug delivery devices that distribute medication through the skin allowing for systemic absorption into the bloodstream. These patches are made up of three layers: a backing, a drug reservoir or matrix, and an adhesive layer. The medicine is released in a regulated manner and absorbed through the skin's layers bypassing the gastrointestinal tract and first-pass metabolism.

They are becoming increasingly popular for their versatility and efficacy in delivering drugs and therapeutic substances through the skin making them useful in a variety of applications. One of its key applications is in the treatment of chronic illnesses such as diabetes and hypertension. For example, insulin patches let diabetic patients to regulate their blood sugar levels without the need for needles boosting patient compliance and comfort.

They are expected to become increasingly popular in the future due to technological and material science breakthroughs. Innovations in microneedling and microneedle patches may boost drug absorption rates enabling for the delivery of bigger molecules such as biologics and vaccinations which are generally difficult to administer transdermally.

Global Transdermal Skin Patches Market Dynamics

The key market dynamics that are shaping the global transdermal skin patches market include:

Key Market Drivers:

Rising Prevalence of Chronic Diseases: The rising prevalence of chronic diseases such as diabetes, hypertension, and pain-related disorders is a major driver of the transdermal skin patch industry. These illnesses frequently necessitate long-term medicine making transdermal administration a viable alternative.

Advancements in Drug Delivery Technologies: Innovations in transdermal delivery methods such as microneedles, nanotechnology, and better skin permeation techniques have considerably improved skin patch efficacy and adaptability. These developments allow for the delivery of a wider spectrum of drugs including biologics and bigger molecules that were previously difficult to administer using traditional methods.

Growing Demand for Patient Compliance and Convenience: Transdermal patches are becoming increasingly popular as a user-friendly alternative to oral drugs and injections, hence improving patient compliance. Patches are popular among patients because they are simple to use, painless to apply, and require less frequent administration.

Key Challenges:

Limited Drug Formulation Compatibility: Not all drugs can be adequately packaged as transdermal patches. Certain medications have limited capacity to permeate the epidermal barrier due to their molecular size and characteristics. This limits the variety of therapies that can be administered transdermally resulting in a smaller market scope than oral or injectable options.

Skin Irritation and Allergic Reactions: Some users may have skin irritation, allergic reactions, or discomfort as a result of continuous patch use. These side effects might contribute to lower patient compliance as discomfort may dissuade people from following their prescribed treatment regimens. Manufacturers must constantly address biocompatibility and skin tolerance issues in order to improve patient acceptance.

Manufacturing and Quality Control: Transdermal patches are manufactured using complicated techniques and strong quality control measures. Variations in manufacturing conditions can cause discrepancies in medication delivery rates and patch function. Ensuring consistency and maintaining good quality throughout the manufacturing process is critical but it can be difficult, particularly for smaller enterprises without advanced technologies.

Key Trends:

Technological Advancements: Significant advances in materials and manufacturing techniques are improving the efficacy and safety of transdermal patches. Microneedle technology, for example, enables more efficient medication delivery by forming micro-channels in the skin resulting in faster absorption. Furthermore, the use of smart technologies, such as sensors that monitor medicine administration and patient adherence, is gaining popularity.

Growing Demand for Chronic Disease Management: The increasing prevalence of chronic diseases such as diabetes, hypertension, and pain management problems is driving up demand for transdermal skin patches. These patches provide a simple, non-invasive alternative to oral drugs, thereby increasing patient compliance and quality of life.

Patient-Centric Solutions: There is an increasing emphasis on personalized medicine and patient-centered healthcare solutions. Transdermal patches are being produced to meet unique patient needs such as changing doses and adjustable delivery profiles. This approach is especially essential in pain management as customized patches can provide precise alleviation.

Global Transdermal Skin Patches Market Regional Analysis

Here is a more detailed regional analysis of the global transdermal skin patches market:

North America:

North America dominates the transdermal skin patches market with the United States taking the lead. This dominance stems mostly from the high frequency of chronic diseases, an aging population, and improved healthcare infrastructure. The increasing frequency of chronic diseases in North America is a major driver of the transdermal skin patch market. According to the Centers for Disease Control and Prevention (CDC), by 2021, 6 out of 10 adults in the United States will have a chronic disease, with 4 out of 10 having two or more. Diabetes affects around 37 million Americans (11.3% of the population), and it is commonly treated using transdermal patches.

The National Institutes of Health (NIH) invested USD 41.7 Billion in medical research in 2020, which could aid transdermal patch technology development. The United States Bureau of Labor Statistics predicts a 9% increase in medical scientist employment from 2020 to 2030, reflecting continuous research into drug delivery techniques. The United States Department of Health and Human Services predicted that national health expenditures would exceed USD 4.1 Trillion in 2020, or $12,530 per person, indicating the significant healthcare spending that supports sophisticated medication delivery technologies such as transdermal patches.

Asia Pacific:

The Asia Pacific region is projected to experience rapid growth in the transdermal skin patches market owing to the rapidly aging population and rising prevalence of chronic disorders. This fast expansion is being driven by the region's enormous customer base, improved healthcare infrastructure, and growing healthcare costs. The elderly population in Asia Pacific is a major driver of the transdermal skin patch market. According to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), the region's elder population (aged 65 and more) is predicted to more than double, from 651 million in 2020 to around 1.3 billion by 2050.

Furthermore, the WHO reports that cardiovascular disorders account for 31% of all deaths in Southeast Asia, indicating a significant market for transdermal patches used in cardiovascular therapy. In China, the National Health Commission reported that 34% of individuals had chronic diseases in 2020, affecting 390 million people. This high incidence rate fuels the demand for novel medicine delivery technologies such as transdermal patches. Furthermore, healthcare spending in the region is increasing, with the World Bank reporting that current health expenditure per capita in East Asia and Pacific increased by 62.5% from $571 in 2010 to $928 in 2019, indicating increased investment in healthcare technologies such as transdermal patches.

Global Transdermal Skin Patches Market: Segmentation Analysis

The Global Transdermal Skin Patches Market is segmented based on Product Type, Application, and Geography.

Transdermal Skin Patches Market, By Product Type

  • Single-layer Drug-in-Adhesive
  • Multi-layer Drug-in-Adhesive
  • Reservoir
  • Vapor Patch
  • Matrix

Based on the Product Type, the Global Transdermal Skin Patches Market is a bifurcated into Single-layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Reservoir, Vapor Patch, and Matrix. In the global transplant diagnostics market, multi-layer drug-in-adhesive products are anticipated to be the dominant segment. This dominance stems from their ability to provide sustained drug release which is critical in transplant procedures requiring precise medication management. Multi-layer systems allow for the controlled delivery of immunosuppressive drugs reducing the risk of rejection while minimizing side effects. Their enhanced efficacy and flexibility in formulation make them suitable for various applications in transplant diagnostics.

Transdermal Skin Patches Market, By Application

  • Neurologic Conditions
  • Pain Management
  • Nicotine Cessation
  • Cardiovascular

Based on the Application, the Global Transdermal Skin Patches Market is bifurcated into Neurologic Conditions, Pain Management, Nicotine Cessation, and Cardiovascular. In the global transdermal skin patches market, pain management is the dominant application segment. This dominance is attributed to the increasing prevalence of chronic pain conditions such as arthritis and back pain which significantly impacts the quality of life for many individuals. Transdermal patches offer a convenient, non-invasive method for delivering analgesics directly into the bloodstream ensuring steady medication levels and reducing the risk of side effects associated with oral medications. Additionally, the growing trend toward personalized medicine and patient-centric treatment options further enhances the appeal of pain management patches.

Transdermal Skin Patches Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Geography, the Global Transdermal Skin Patches Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. The North American region dominates the global transdermal skin patches market accounting for a significant share due to several key factors. Firstly, the region boasts advanced healthcare infrastructure leading to higher adoption rates of innovative drug delivery systems. The presence of major pharmaceutical companies and ongoing research and development initiatives further drive market growth. Additionally, a growing prevalence of chronic diseases such as diabetes and hypertension increases the demand for convenient drug delivery options.

Key Players

The "Global Transdermal Skin Patches Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Teva Pharmaceuticals USA, Inc., Novartis AG, Teikoku Pharma USA Inc., Mylan, Inc., 3M, Luye Pharma Group, Purdue Pharma Manufacturing LP, Henan Lingrui Pharmaceutical Ltd, and Mundipharma.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Transdermal Skin Patches Market Key Developments

  • In September 2023, Corium, LLC, a biopharmaceutical company, revealed data proving the effectiveness of its donepezil transdermal system, ADLARITY, in a placebo-controlled trial of healthy volunteers. It is the first donepezil transdermal system authorized by the FDA in the United States for the treatment of mild, moderate, and severe Alzheimer's dementia.
  • In September 2023, Zydus Lifesciences Ltd announced that it had received final FDA approval for its Norelgestromin and Ethinyl Estradiol Transdermal System. This skin patch distributes a combined hormone medicine that effectively prevents pregnancy.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL TRANSDERMAL SKIN PATCHES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL TRANSDERMAL SKIN PATCHES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL TRANSDERMAL SKIN PATCHES MARKET, BY PRODUCT TYPE

  • 5.1 Overview
  • 5.2 Single-layer Drug-in-Adhesive
  • 5.3 Multi-layer Drug-in-Adhesive
  • 5.4 Reservoir
  • 5.5 Vapour Patch
  • 5.6 Matrix

6 GLOBAL TRANSDERMAL SKIN PATCHES MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Neurologic Conditions
  • 6.3 Pain Management
  • 6.4 Nicotine Cessation
  • 6.5 Cardiovascular

7 GLOBAL TRANSDERMAL SKIN PATCHES MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East & Africa

8 GLOBAL TRANSDERMAL SKIN PATCHES MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Teva Pharmaceuticals USA Inc.
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Novartis AG
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Teikoku Pharma USA Inc.
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Mylan Inc.
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 3M
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Luye Pharma Group
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Purdue Pharma Manufacturing LP
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Henan Lingrui Pharmaceutical Ltd
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Mundipharma
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments

10 KEY DEVELOPMENTS

  • 10.1 Product Launches/Developments
  • 10.2 Mergers and Acquisitions
  • 10.3 Business Expansions
  • 10.4 Partnerships and Collaborations

11 Appendix

  • 11.1 Related Research